IGC Pharma, Inc. (IGC)

Market Cap	23.59M
Revenue (ttm)	1.24M
Net Income (ttm)	-8.81M
Shares Out	79.69M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	321,139
Open	0.306
Previous Close	0.296
Day's Range	0.294 - 0.309
52-Week Range	0.270 - 0.910
Beta	1.32
Analysts	Strong Buy
Price Target	3.75 (+1,166.89%)
Earnings Date	Mar 4, 2025

About IGC

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 67
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: IGC
• Website: https://igcpharma.com

Financial Performance

In 2023, IGC Pharma's revenue was $1.35 million, an increase of 47.64% compared to the previous year's $911,000. Losses were -$13.00 million, 13.0% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for IGC stock is "Strong Buy." The 12-month stock price forecast is $3.75, which is an increase of 1,166.89% from the latest price.

Price Target

$3.75

(1,166.89% upside)

Analyst Consensus: Strong Buy